Shorted
Immutep logo
IMM
Pharmaceuticals, Biotechnology & Life Sciences

Immutep

Short interest
1.23%
−0.89 pp 30d
as of 8 Oct 2026
Reported shorts
18.1M
Shares on issue
1.474B

Immutep (IMM) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
17 Sept

What Is Driving Fresh Attention Around Immutep (ASX:IMM) Today?

Highlights Immutep is in focus after fresh same-day trading activity among low-priced healthcare shares. The update keeps attention on biotechnology research and the companys next operational steps. The broader Penny Stocks theme remains centred on execution, disclosure quality and strategic follow-through. Further company updates will help clarify how todays development fits into the longer operating pathway. Immutep (ASX:IMM) is drawing attention today after fresh same-day trading activity ...

Continue reading
Kalkine
Neutral
11 Sept

Immutep ASX:IMM Resets Efti Development Path After Major Trial Setback

Highlights Immutep turns to a fresh manufacturing batch after a clinical setback. Batch differences emerge between earlier and later production processes. Future development will target head and neck cancer and sarcoma. Immutep is restructuring the development pathway for eftilagimod alfa after manufacturing differences were identified during an investigation into an unexpectedly unsuccessful clinical study. Immutep reassesses its clinical development strategy Australian biotechnology co...

Continue reading
Kalkine
Neutral
3 Sept

Is Immutep (ASX:IMM) Drawing Attention Among Healthcare Stocks?

Highlights Pooled trial data across several cancer types linked an immune response to efti with meaningfully longer survival. A separate late-stage lung cancer trial was stopped early after an interim analysis found it unlikely to succeed. A second pipeline candidate cleared its main safety objective in an early-phase human trial. Immutep Limited (ASX:IMM), the Sydney-based immunotherapy developer, presented pooled trial data showing patients who responded immunologically to its lead drug can...

Continue reading
Kalkine
Negative
31 Aug

Immutep Reports $79.3M Annual Loss Amid Rising R&D Expenses and Halt of TACTI-004 Phase III Trial

Immutep Limited (ASX:IMM) announced a net loss of $79,304,563 for the fiscal year ending 30 June 2026, marking a 29.1% increase from the previous year's loss of $61,434,165, as detailed in the company’s preliminary final and annual reports filed on 31 August 2026. Key Points Net loss attributable to Immutep shareholders rose 29.1% to $79,304,563 for the year ended 30 June 2026 FY2026 revenue from ordinary activities reached $14,556,923, mainly driven by licensing and collaboration with Dr R...

Continue reading
Kalkine
Neutral
24 June

Immutep (ASX:IMM): Why These ASX Penny Stocks Are Drawing Attention

Highlights Immutep, Orbital and Turaco Gold are gaining attention for their strong balance sheets and sector-specific growth initiatives. The three companies operate across healthcare innovation, defence technology and gold exploration. Financial strength remains a key differentiator among smaller ASX-listed companies navigating uncertain market conditions. Immutep, Orbital and Turaco Gold are attracting attention through strong financial positions and exposure to healthcare innovation, aeros...

Continue reading